E2 ModeratePreliminaryPEM unclearObservationalPeer-reviewedMachine draft
Maintenance of Chronic Fatigue Syndrome (CFS) in Young CFS Patients Is Associated with the 5-HTTLPR and SNP rs25531 A > G Genotype.
Meyer, Benedicte, Nguyen, Chinh Bkrong Thuy, Moen, Aurora et al. · PloS one · 2015 · DOI
Quick Summary
This study looked at whether differences in a specific gene related to serotonin (a brain chemical) might affect how severe ME/CFS stays in young patients. Researchers found that teenagers with certain versions of this gene had worse physical activity levels and greater disability 30 weeks later compared to those with other versions. This suggests that your genes may play a role in whether your ME/CFS improves or stays the same.
Why It Matters
Understanding genetic factors that influence ME/CFS severity and persistence could eventually help identify which patients are at higher risk for prolonged illness and might benefit from personalized treatment approaches. This type of biomarker research provides a foundation for moving beyond one-size-fits-all management strategies in ME/CFS.
Observed Findings
- Patients with 5-HTT SS or SLG genotypes had significantly lower daily step counts than those with LALG, SLA, or LALA genotypes.
- Patients with SS or SLG genotypes had significantly higher Functional Disability Inventory scores (greater disability) than those with LALG, SLA, or LALA genotypes.
- Differences in physical activity and disability persisted at the 30-week follow-up assessment.
- The study enrolled 120 young CFS patients (ages 12–18) from a specialized national referral center.
Inferred Conclusions
- Serotonin transporter genotype may be a contributing factor to CFS maintenance in young patients.
- Certain 5-HTT gene variants (SS and SLG) are associated with worse functional outcomes over a 30-week period.
- Genetic variation in serotonin reuptake capacity may influence physical functioning and disability severity in ME/CFS.
Remaining Questions
- Does the 5-HTT genotype predict treatment response to serotonergic medications or other interventions in ME/CFS?
- What is the mechanism by which these gene variants influence CFS trajectory—is it primarily neurobiological, immunological, or mediated through psychological factors?
- Do these findings replicate in adult CFS populations and in different geographic or ethnic groups?
What This Study Does Not Prove
This study does not prove that the 5-HTT gene causes CFS or determines who will develop it—only that certain variants may be associated with worse outcomes in those already diagnosed. The observational design cannot establish causation or rule out confounding variables. Results require replication in independent cohorts and validation of the biological mechanism.
Tags
Symptom:Fatigue
Biomarker:Gene Expression
Phenotype:Pediatric
Method Flag:PEM Not DefinedWeak Case DefinitionSmall SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →